[HTML][HTML] Developments in small molecule antiviral drugs against hepatitis B and C viruses: FDA approved therapies and new drugs in clinical trials
PK Parikh, NH Parikh, B Mahalakshmi… - Arabian Journal of …, 2023 - Elsevier
Given the continuous emergence of hepatitis and the associated consequences, developing
effective antiviral strategies has become a major public health concern. Current antiviral …
effective antiviral strategies has become a major public health concern. Current antiviral …
[HTML][HTML] Alternative pharmaceutical innovation models in competitive markets: A collaborative approach to develop a novel drug for Hepatitis C
Alternative innovation models have emerged to address failures of the traditional
pharmaceutical system, particularly for diseases where market incentives do not attract …
pharmaceutical system, particularly for diseases where market incentives do not attract …
Methadone maintenance treatment for opioid dependents: A retrospective study
K Khalid, YT Ooi, QA Rashid… - East Asian Archives …, 2022 - search.informit.org
Objectives: To determine the prevalence of continued illicit drug use among people enrolled
in methadone maintenance treatment (MMT), the association between hepatitis C status and …
in methadone maintenance treatment (MMT), the association between hepatitis C status and …
[HTML][HTML] CROI 2022: Advances in Antiviral Therapy for HIV, COVID-19, and Viral Hepatitis
SH Gunaratne, HV Tieu, TJ Wilkin… - Topics in Antiviral …, 2022 - ncbi.nlm.nih.gov
Abstract The 2022 Conference on Retroviruses and Opportunistic Infections provided a rich
source of new data and comprehensive reviews on antiviral therapy. For COVID-19 …
source of new data and comprehensive reviews on antiviral therapy. For COVID-19 …
Alternative pharmaceutical innovation models in competitive markets: a collaborative approach to develop a novel drug for hepatitis C
Alternative innovation models have emerged to address failures of the traditional
pharmaceutical system, particularly for diseases where market incentives do not attract …
pharmaceutical system, particularly for diseases where market incentives do not attract …
[PDF][PDF] Early Access To New Direct-Acting Antiviral: A Journey On Introduction Of Ravidasvir For Hepatitis C Treatment In Malaysia
NS Idrus - 2030 - researchgate.net
Early Access To New Direct-Acting Antiviral: A Journey On Introduction Of Ravidasvir For
Hepatitis C Treatment In Malaysia Page 1 Early Access To New Direct-Acting Antiviral: A …
Hepatitis C Treatment In Malaysia Page 1 Early Access To New Direct-Acting Antiviral: A …